The Pharmaletter

Accord Healthcare

A multinational pharmaceuticals company with its main European headquarters in the United Kingdom and operating affiliates across Europe and other international markets. The group supplies medicines in more than 80 countries, with a significant footprint in hospital channels as well as retail generics and biosimilars.

Founding and History

Accord Healthcare developed as the international business associated with Intas Pharmaceuticals, expanding from generics into biosimilars and specialty brands. Over the past decade it has broadened its European portfolio and commercial infrastructure, while building additional capability in biosimilars and complex products. In 2025, Accord continued a strategy of portfolio expansion and inorganic growth, including entry into plasma-derived medicines via acquisition.

Therapy Areas and Focus

Accord’s portfolio spans both pharmacy generics and hospital/specialty medicines. Its named commercial franchises include:

Oncology and haematology
Autoimmune disease
Central nervous system
Critical care

Across these areas, Accord markets a mix of generics, biosimilars, and branded specialty products.

Technology Platforms and Modalities

Accord is primarily a development, manufacturing, and commercialization organization for generics and biosimilars rather than a novel-discovery biotech. Its capabilities include:

Small-molecule generics across oral and injectable dosage forms
Biosimilars, including in bone health and supportive care
Specialty brands, often differentiated through formulation, presentation, or delivery features rather than new molecular entities

Key Personnel

Paul Tredwell is Global Chief Executive Officer, appointed in 2025.

Strategic Partnerships

Accord operates within the Intas group and uses partnerships and acquisitions to expand capabilities and geographic reach. In 2025 it completed the acquisition of Prothya Biosolutions, adding plasma-derived medicinal product capability. In the U.S., Accord’s business includes a specialty division operating under the Accord BioPharma name and has expanded its biosimilar portfolio through acquisition activity.

FAQ Section

Accord Healthcare develops, manufactures, and commercializes a broad portfolio of generics, biosimilars, and specialty brands, with a particular concentration in hospital and specialist medicines alongside large-scale pharmacy generics.

Accord’s marketed portfolio is organized around four core franchises: oncology and haematology, autoimmune disease, central nervous system, and critical care, supported by a broader generics base across multiple therapeutic categories.

Accord’s development work is centered on lifecycle expansion of generics and biosimilars and on portfolio additions through licensing and acquisition. Recent examples include biosimilars in bone health and supportive care and expansion of plasma-derived medicines capability following acquisition.

In September 2025, Accord appointed Paul Tredwell as Global CEO. In October 2025, the company completed the acquisition of Prothya Biosolutions. In December 2025, Accord announced the European launch of denosumab biosimilars, marketed as Osvyrti and Jubereq, following loss of exclusivity of the reference products.

For biosimilars, Accord’s public disclosures typically reference comparative clinical and analytical packages supporting regulatory approvals, consistent with biosimilar development requirements, rather than novel efficacy-discovery programs.

Near-term milestones are driven by market launches, geographic rollouts, and regulatory approvals for additional biosimilars and complex generics, alongside integration and operational scaling following the Prothya acquisition.

Accord is led by executives with experience in European generics, biosimilars commercialization, and supply operations, with 2025 leadership changes aligned to the company’s continued expansion in biosimilars and specialty medicines.

Want to Update your Company's Profile?